Is it appropriate to hold HIV antiretroviral medications in a patient who is nil per os (NPO) due to a bowel obstruction?

Do Not Hold HIV Medications for NPO Status Due to Bowel Obstruction

You should continue HIV antiretroviral therapy (ART) in patients who are NPO from bowel obstruction, using alternative routes of administration rather than interrupting treatment. Even brief interruptions of ART risk viral rebound, resistance development, and increased morbidity and mortality.

Key Rationale

The 2025 IAS-USA guidelines emphasize that for those unable to take oral ART, long-acting cabotegravir plus long-acting rilpivirine may be considered for people with viremia when no other treatment options are effective 1. While this recommendation specifically addresses adherence issues, it underscores the critical principle that inability to take oral medications should prompt alternative delivery methods, not treatment interruption.

Alternative Administration Strategies

Nasogastric/Enteral Administration

• Crushed antiretrovirals can be effectively administered via nasogastric tube, even with impaired gastric emptying 2
• A documented case showed crushed dolutegravir/abacavir/lamivudine given via NG tube (clamped overnight, drained during day) achieved viral suppression from 300,000 to <40 copies/mL 2
• Therapeutic drug monitoring confirmed adequate plasma levels despite unconventional administration 2

Parenteral Options

• Intravenous antiretrovirals (such as albuvirtide) can maintain viral suppression perioperatively 3
• In surgical patients, short ART interruptions showed minimal impact on viral load in those with prior suppression, but patients with detectable viral loads benefited significantly from IV antiretrovirals 3
• IV options reduced postoperative complications compared to treatment interruption 3

Critical Risks of Holding ART

Even brief treatment interruptions carry substantial risks:

• Viral rebound can occur rapidly, particularly in patients not previously suppressed
• Subtherapeutic drug levels from malabsorption (as occurs with severe diarrhea/bowel dysfunction) are associated with treatment failure 4
• The combination of bowel obstruction and ART interruption creates a "perfect storm" for viral rebound and resistance development

Clinical Algorithm

1. Never simply hold ART - this should be your last resort
2. Assess for NG/enteral tube placement:
   • If present or feasible: crush appropriate medications (check drug-specific crushing compatibility)
   • Administer via tube, consider clamping overnight if gastric emptying is severely impaired 2
3. If enteral route impossible:
   • Consult infectious disease for IV antiretroviral options
   • Consider long-acting injectable formulations if patient meets criteria 1
4. If truly no alternative exists (extremely rare):
   • Document medical necessity
   • Plan for immediate ART resumption when bowel function returns
   • Monitor viral load closely after resumption 5

Important Caveats

• Patients with prior viral suppression tolerate brief interruptions better than those with detectable viral loads 3, but this doesn't justify routine holding
• The malabsorption from bowel obstruction itself may already compromise drug levels 4, making intentional interruption even more dangerous
• Check for drug-drug interactions between ART and any medications used to manage the bowel obstruction
• Some antiretrovirals cannot be crushed (extended-release formulations, enteric-coated tablets) - verify before crushing

Special Considerations

For patients requiring surgery for bowel obstruction, perioperative continuation of ART (via alternative routes) reduces postoperative infectious complications 3. The surgical team's infection risk is also reduced when viral loads remain suppressed.

The bottom line: Bowel obstruction is a reason to find alternative ART delivery methods, not to interrupt life-sustaining therapy.